

MORBIDITY AND MORTALITY

WEEKLY REPORT

- 813 Human Ingestion of Bacillus Anthracis-Contaminated Meat — Minnesota, August 2000
- 816 Outbreak of Acute Febrile Illness Among Participants in EcoChallenge Sabah 2000 — Malaysia, 2000
- 818 Screening With the Prostate-Specific Antigen Test — Texas, 1997
- 820 Update: West Nile Virus Activity Northeastern United States, 2000
- 831 Notice to Readers

Human Ingestion of Bacillus Anthracis-Contaminated Meat — Minnesota, August 2000

On August 25, 2000, the Minnesota Department of Health (MDH) was notified by the Minnesota Board of Animal Health (MBAH) of *Bacillus anthracis* isolated from a steer on a farm in Roseau County, Minnesota. The infected steer was one of five dead cattle found in a pasture on August 20. On the basis of phage typing of isolates cultured from tissues and blood samples by the North Dakota State University Veterinary Diagnostic Laboratory, *B. anthracis* was confirmed. This report describes the management of and public health response to human exposure to meat contaminated with anthrax.

On July 24, the farmer who owned the infected steer also had killed, gutted, and skinned a cow that was unable to rise. A local veterinarian approved the slaughter of the cow for consumption by the farmer's family. Immediately after slaughter, the farmer took the carcass (carcass X) to a custom meat-processing plant; on July 31 and August 1, carcass X was processed. Two family members ate hamburgers made from carcass X on August 15 and steaks on August 19; three other family members ate hamburgers on August 20. A sixth member prepared the meals and also may have eaten contaminated meat. All meat was reported to have been well cooked. To investigate the possibility that they had eaten contaminated meat, the family members were interviewed by MDH on August 25. Two reported gastrointestinal illness; one reported 1 day of diarrhea approximately 48 hours after eating meat from carcass X, and the second reported 3 days of abdominal pain, diarrhea, and a temperature of 102.3 F (39.1 C) beginning 24–36 hours after consumption. Both recovered without treatment. The family was advised by MDH not to eat any more of the meat, to contact a physician, and to begin antibiotic prophylaxis with ciprofloxacin (500 mg, orally, twice daily).

On August 29, samples of carcass X tested by the MDH Public Health Laboratory (MDH PHL) were found to contain gram-positive bacilli on microscopic examination. *B. anthracis* contamination was confirmed at MDH PHL and the U.S. Army Medical Research Institute for Infectious Diseases through culture on blood agar, presence of a capsule, lack of motility, gamma-phage test, and fluorescent antibody to cell wall polysaccharide and capsular antigens. On the basis of this exposure to meat highly contaminated with *B. anthracis*, the family was advised to continue chemoprophylaxis, and vaccination with anthrax vaccine was initiated (Anthrax Vaccine Adsorbed*, Bioport Corporation, Lansing, Michigan).

^{*} Use of trade names and commercial sources is for identification only and does not constitute endorsement by CDC or the U.S. Department of Health and Human Services.

Bacillus Anthracis — Continued

The Minnesota Department of Agriculture (MDA) contacted the custom meat processing plant on August 28 and placed a hold on all meat processed after carcass X. On August 29, MDA inspected the plant; sanitation practices were satisfactory. Seven carcasses had been processed after carcass X. Owners of meat from the carcasses were advised not to eat any of the meat and were asked to return meat to a central location for incineration; all the meat products were accounted for and none had left Minnesota. Samples from the other carcasses and environmental swabs collected after plant cleaning tested negative for *B. anthracis*.

Reported by: H Kassenborg, DVM, R Danila, PhD, P Snippes, MT(ASCP), M Wiisanen, M Sullivan, MPH, KE Smith, DVM, N Crouch, PhD, C Medus, MPH, R Weber, MS, J Korlath, MPH, T Ristinen, R Lynfield, MD, HF Hull, MD, Minnesota Dept of Health. J Pahlen, Roseau County Home Health Care, Roseau; T Boldingh, DVM, Minnesota Board of Animal Health, K Elfering, G Hoffman, Minnesota Dept of Agriculture, St. Paul. T Lewis, A Friedlander, MD, H Heine, PhD, R Culpepper, MD, E Henchal, PhD, G Ludwig, PhD, C Rossi, MS, J Teska, PhD, J Ezzell, PhD, E Eitzen, MD, US Army Medical Research Institute for Infectious Diseases. Food Safety and Inspection Svc, Animal and Plant Health Inspection Svc, US Dept of Agriculture. Epidemiology Program Office, Meningitis and Special Pathogens Br, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases; and an EIS Officer, CDC.


Editorial Note: Anthrax is a zoonotic disease caused by the spore-forming bacterium *B. anthracis*. Human disease usually occurs through cutaneous exposure to infected animal tissue or products. Rarely, inhalation or ingestion of *B. anthracis* spores also leads to anthrax. In the United States during the early part of the 20th century, approximately 130 human cases occurred annually (*1*); two cutaneous infections have been reported since 1992.

Before this exposure, no animal anthrax cases had been reported in northern Minnesota since recordkeeping began in 1909. However, in adjacent areas of North Dakota during 2000, 120–150 cattle have died of anthrax (L. Schuler, North Dakota state veterinarian, personal communication, 2000), and 11 farms have reported anthrax-related cattle deaths in nearby Manitoba, Canada (Figure 1) (J.G. Spearman, Manitoba Department of Agriculture, personal communication, 2000).

Gastrointestinal anthrax in humans occurs 1–7 days after eating raw or undercooked meat from infected animals (2), and two forms of gastrointestinal disease have been reported (3). Disease affecting the distal gastrointestinal tract results in nausea, anorexia, and fever followed by abdominal pain and bloody stool. The case fatality rate among reported cases ranges from 25%–60% (2). Gastrointestinal anthrax never has been documented in the United States because livestock are vaccinated for anthrax in areas where the disease is endemic; animals routinely are inspected by federal and state meat inspectors before, during, and after slaughter; and raw meat is eaten infrequently. Anthrax has not been documented among the persons exposed to *B. anthracis*-contaminated meat described in this report; however, a serologic test to determine presence of infection is pending.

Limited experience with gastrointestinal anthrax complicates recommendations for use of postexposure prophylaxis. An extended duration of therapy is recommended for inhalational exposure because of the persistence of spores resistant to the action of antimicrobial agents (4,5). Upon cessation of chemoprophylaxis, such spores can cause disease several weeks after exposure. No evidence supports the existence of persistent spores associated with gastrointestinal forms of the disease; however, the meat consumed by the family in this report was highly contaminated with *B. anthracis*. Although

Bacillus Anthracis — Continued





possible interventions range from close observation to antibiotics alone to antibiotics with vaccination, because the family was at high risk for anthrax infection, management consisted of an extended course of ciprofloxacin combined with administration of anthrax vaccine.

Federal-inspected and state-inspected animal processing facilities are required to perform intensive cleaning after contact with an anthrax-infected carcasses[†]; veterinary inspection is not provided at custom meat processors. Slaughter house workers who may be exposed to an anthrax-contaminated carcass should receive medical evaluation for symptoms and for possible treatment. Management of anthrax in livestock should include 1) quarantine of the herd; 2) removal of the herd from the contaminated pasture, if possible; 3) vaccination of healthy livestock; 4) treatment of symptomatic livestock; and 5) disposal of infected carcasses, preferably by burning. Bedding and other material found around the carcass (e.g., soil) should be incinerated with the carcass and buried (6).

Veterinarians notified of sudden death in an animal or of an animal unable to rise should consider anthrax as a diagnosis, especially in areas where anthrax is endemic (6). However the potential risk for animal anthrax exists in all areas of the United States.

[†]9 CFR Part 310.9 (2000).

Bacillus Anthracis — Continued

Vaccination of livestock in areas where anthrax is endemic is the most effective method of prevention in animals and humans. Cases of anthrax in animals and cases of suspected human exposure should be reported immediately to the state health department, federal animal heath officials, and to CDC's National Center for Infectious Diseases, Meningitis and Special Pathogens Branch, telephone (404) 639-3158.

References

- 1. Brachman P, Friedlander A. Anthrax. In: Plotkin S, Mortimer E, eds. Vaccines. 2nd ed. Philadelphia, Pennsylvania: WB Saunders Co., 1994:792–39.
- 2. Brachman P, Kaufmann A. Anthrax. In: Evans A, Brachman P, eds. Bacterial infections of humans. New York, New York: Plenum Medical Book Company, 1998.
- Sirisanthana T, Navachareon N, Tharavichitkul P, Sirisanthana V, Brown AE. Outbreak of oral-oropharyngeal anthrax: an unusual manifestation of human infection with *Bacillus anthracis*. Am J Trop Med Hyg 1984;33:144–50.
- 4. CDC. Bioterrorism alleging use of anthrax and interim guidelines for management—United States, 1998. MMWR 1999;48:69–74.
- 5. Friedlander AM, Welkos SL, Pitt ML, et al. Post-exposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993;167:1239–43.
- Animal Plant Health Inspection Service. Washington, DC: US Department of Agriculture Veterinary Services, US Department of Agriculture. September 1999. Available at http:// www.aphis.usda.gov/oa/pubs/anthrax.html. Accessed September 2000.

Public Health Dispatch

Outbreak of Acute Febrile Illness Among Participants in EcoChallenge Sabah 2000 — Malaysia, 2000

On September 7, 2000, CDC was notified by Idaho Department of Health about a case of acute febrile illness in a 35-year-old man; the illness was characterized by acute onset of high fever, chills, headache, and myalgias. The patient had participated in the EcoChallenge Sabah 2000 Expedition Race, a multisport event held during August 20–September 3, at various sites in Sabah in Malaysian Borneo.

This report presents preliminary findings of an ongoing investigation to identify cases of acute febrile illness among athletes who participated in the EcoChallenge Race in Borneo during August 2000. Preliminary laboratory test results indicate the probable cause of illness to be leptospirosis, a spirochete infection. The event involved jungle trekking, open water swimming, river and ocean paddling, mountain biking, canyoneering, scuba diving, and spelunking. Participating were 76 four-person teams from 26 countries, including 37 teams from the United States. Subsequently, nine other EcoChallenge participants who became ill were identified in California (five in San Diego County, two in Orange County, and two in Los Angeles). To identify additional athletes with febrile illness, an EcoChallenge participant list was obtained from race organizers, and a telephone survey was administered by CDC with the assistance of several state public health departments. As of September 13, 82 (53%) of 155 U.S.-based athletes have been contacted; 37 (45%) reported having fever and 12 (15%) were hospitalized. No deaths have been reported.

Acute Febrile Illness — Continued

On September 12, serum specimens obtained from two hospitalized athletes from Los Angeles were tested at CDC for leptospirosis using the Dip-S-Ticks* assay (Leptospira INDX Dip-S-Ticks; Integrated Diagnostics, Baltimore, Maryland) and the Pan-Bio* enzyme-linked immunosorbent assay (ELISA) IgM test (PanBio, Brisbane, Australia). One athlete tested positive with both tests on an acute-phase serum specimen obtained 4 days following onset of fever. The second athlete tested negative with both tests on the acute-phase specimen but positive with both tests on a follow-up specimen obtained 4 and 6 days following onset of fever.

On the basis of laboratory test results and the clinical features of illness, CDC advises the following to clinicians caring for EcoChallenge participants. First, asymptomatic athletes that were taking chemoprophylaxis for leptospirosis (i.e., 200 mg oral doxycycline weekly) should ensure that their final weekly dose was taken following completion of the race (1). Second, although the merits of one dose of postexposure chemoprophylaxis with 200 mg oral doxycycline are unknown, asymptomatic athletes who participated in the race and who were not taking chemoprophylaxis for leptospirosis may wish to discuss the single-dose option with their physician. Third, for athletes with mild symptoms consistent with leptospirosis, treatment should include 7 days of oral doxycycline, 100 mg twice daily (2). Finally, for hospitalized patients with severe illness (e.g., persistent high-grade fever, impaired hepatic or renal function, or severe neurologic disturbances, including coma, hemiplegia, or transverse myelitis), treatment should include 7 days of intravenous penicillin G, 1.5 million units every 6 hours (3). As with other spirochete infections, a Jarisch-Herxheimer reaction can develop following the initiation of penicillin therapy for leptospirosis (4). Although these reactions serve as an indicator of therapeutic efficacy, they can be associated with increased morbidity and mortality; patients receiving intravenous penicillin should be monitored for shocklike symptoms.

On September 13, CDC issued an advisory (http://webdev.cdc.gov/travel/other/leptomalaysia.htm) about the probable leptospirosis outbreak associated with the EcoChallenge event to raise awareness among health-care workers and participants of the event in Borneo. The Meningitis and Special Pathogens Branch (MSPB) at CDC is interested in receiving reports through state and local health departments of additional participants who have been ill or have had fever since August 21. In addition, MSPB will test clinical specimens for leptospirosis received through state and local health departments.

Reported by: California Dept of Health. Idaho Dept of Health. Council of State and Territorial Epidemiologists, Atlanta, Georgia. Meningitis and Special Pathogens Br, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases; and EIS officers, CDC.

References

- Takafuji ET, Kirkpatrick ET, Miller JW, et al. An efficacy trial of doxycycline chemoprophylaxis against leptospirosis. N Engl J Med 1984;310:497–500.
- McClain BL, Ballou WR, Harrison SM, Steinweg DL. Doxycycline therapy for leptospirosis. Ann Intern Med 1984;100:696–8.
- 3. Watt G, Padre LP, Tuazon ML, et al. Placebo-controlled trial of intravenous penicillin for severe and late leptospirosis. Lancet 1988;8563:433–5.
- 4. Tappero JW, Ashford DA, Perkins BA. *Leptospira* species (Leptospirosis) 5th ed. In: Mandell GL, Bennet JE, Dolin R, eds. Principles and practice of infectious diseases. New York, New York: Churchill Livingstone, 1999;2495–501.

^{*}Use of trade names and commercial sources is for identification only and does not constitute endorsement by CDC or the U.S. Department of Health and Human Services.

Screening With the Prostate-Specific Antigen Test — Texas, 1997

Prostate cancer is the second leading cause of cancer-related deaths among men in Texas (1). From 1990 to 1997, the average annual number of prostate cancer-related deaths in Texas was 1900, and the average annual death rate was 20.9 per 100,000 population (1). An estimated 10,186 new prostate cancer cases will occur in 2000 in Texas (2). Several screening methods are available for early detection of prostate cancer, including digital rectal exam, transrectal ultrasound, and prostate-specific antigen (PSA) testing, which involves a simple phlebotomy (3). To assess the proportion of men in Texas receiving PSA testing and to identify factors associated with receipt of this testing, the Texas Department of Health added three questions to its 1997 Behavioral Risk Factor Surveillance System (BRFSS) survey relating to PSA testing. This report summarizes this analysis and indicates that approximately 37% of men aged \geq 40 years had received PSA testing and that receipt of PSA testing was associated with a doctor's recommendation.

BRFSS is a state-based, random-digit-dialed telephone survey of the civilian, noninstitutionalized U.S. population aged ≥18 years. In 1997, men aged ≥40 years who responded to the Texas BRFSS were asked, "Have you heard about the PSA blood test?", "Have you ever been told by a doctor that you should have a PSA blood test?", and "Have you ever had a PSA blood test?" Responses were weighted to provide statewide estimates; standard errors and 95% confidence intervals (CIs) were calculated, and univariate and multivatiate analyses were performed using SUDAAN.

Among respondents, 60% (95% CI=55%–65%) said they had heard of the PSA test. Of those who had heard of the test, 52% (95% CI=45%–59%) were told by their doctor that they should receive the test. Of those who had heard of the test and whose doctor recommended it, 91% (95% CI=85%–96%) reported having received the test. Overall, 37% (95% CI=32%–42%) of men received the PSA test, representing approximately 62% of men who had heard of the test. Of those who were not told by a doctor to have the test, 24% (95% CI=14%–30%) received the test.

Univariate analysis indicated that receiving the PSA test was associated with a doctor's recommendation (odds ratio [OR]=28.2; 95 Cl=13.3–59.8) (Table 1). Other factors associated with receiving the test were having had a physical examination during the preceding 2 years (OR=5.4; 95 Cl=2.6–11.0), being aged \geq 50 years (OR=5.2; 95 Cl=5.1–5.2), being covered by a health plan (OR=3.8; 95 Cl=2.0–7.1), having ever received a proctoscopic examination (OR=3.4; 95 Cl=2.0–5.7), being non-Hispanic (OR=2.2; 95 Cl=2.2–2.3), and having \geq 16 years of education (OR=1.9; 95 Cl=1.2–3.0). Logistic regression analysis indicated that receiving a PSA test was associated with a doctor's recommendation (adjusted OR=80.4; 95% Cl=21.4–301.9), and being aged >50 years (adjusted OR=4.0; 95% Cl=1.3–12.3).

Reported by: K Condon, Behavioral Risk Factor Surveillance System Program, L Suarez, PhD, Office of the Associate Commissioner of Disease Control and Prevention, D Perrotta, PhD, State Epidemiologist, Texas Dept of Health. Epidemiology and Health Svcs Research Br, Div of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion; State Br, Div of Applied Public Health Training, Epidemiology Program Office; and an EIS Officer, CDC.

Editorial Note: The findings in this report document a strong association between a doctor's recommendation and receipt of a PSA test, indicating that physician advice is a key determinant of whether men are tested. In Texas, approximately 60% of men who had heard of PSA testing reported receiving the test. Nearly all of the men whose doctor recommended the PSA test took that advice.

Prostate-Specific Antigen Test — Continued

	% T	ested	_			
Factor	With factors	Without factors	Unadjuste odds ratio		Adjusted odds ratio	⁺ (95% CI)
Doctor recommendation	ר 90.1	24.4	28.2	(13.3–59.8)	80.4	(21.4–301.9)
Age ≥50 years	68.4	29.6	5.2	(5.1–5.2)	4.0	(1.3– 12.3)
Physical examination						
during preceding						
2 years	60.1	22.5	5.4	(2.6–11.0)	4.5	(0.4- 21.9)
≥16 years education	45.1	29.6	1.9	(1.2-3.0)	2.0	(0.7-6.4)
Covered by health plan	92.1	7.8	3.8	(2.0- 7.1)	1.7	(0.4-6.3)
Ever had proctoscopic						
examination	72.0	43.0	3.4	(2.0- 5.7)	1.5	(0.5-4.1)
Non-Hispanic	57.4	37.5	2.2	(2.2- 2.3)	1.0	(0.2- 6.7)

TABLE 1. Percentage of men aged \geq 40 years who received a prostate-specific
antigen test, by selected factors — Texas, 1997

* Confidence interval.

[†] Factors included in the logistic regression analysis model for the adjusted odds ratio were told to receive a PSA, ever had a proctoscopic examination, race, age, education level, marital status, having a family member diagnosed with prostate cancer, having a health plan, having a checkup during the preceding 2 years, income, prevented from seeking medical care because of cost, and Hispanic ethnicity.

Prostate cancer screening recommendations differ among national organizations. The American Cancer Society (ACS) recommends that men aged \geq 50 years who receive an annual examination be offered the Digital Rectal Examination and the PSA test (4). ACS also recommends that men aged \geq 40 years be informed about the risk for prostate cancer (5). In comparison, because no evidence exists that early detection and treatment influences the overall death rate from this disease and about half of the men who undergo surgical treatment of localized lesions experience side effects (e.g., incontinence and impotence) (6), the U.S. Preventive Services Task Force, the American College of Physicians, the American Society of Internal Medicine, the National Cancer Institute, the American Association of Family Practitioners, and the American College of Preventive Medicine do not advocate routine screening (7,8). Despite the conflicting recommendations, PSA testing has increased rapidly among asymptomatic men in the United States (9).

The findings in this report are subject to at least four limitations. First, BRFSS questions did not distinguish prostate cancer screening from diagnostic testing. Some respondents may have received PSA testing as part of a diagnostic evaluation for symptoms or to monitor treatment for existing prostate cancer. Second, respondents may have had the PSA test performed, but did not know that it had been done. Third, among men for whom PSA testing was not recommended, it is not possible to distinguish men whose physicians discouraged screening from those whose physicians did not mention screening. Finally, because the survey did not ask men how they heard about the test, the proportion of men hearing about the test from sources other than their doctor is not known.

The findings of this report suggest that interest in prostate cancer and awareness about the available screening tests for this disease is substantial. These data are consistent with information from other studies that indicate a substantial proportion of men aged >40 years have received PSA testing. Because PSA testing potentially can have an

Prostate-Specific Antigen Test — Continued

impact on statistics about prostate cancer incidence and outcomes, ongoing surveillance of the trends and determinants of the use of this procedure are warranted (8). As a result, CDC is incorporating questions about PSA testing in the 2001 BRFSS for every state. This effort, and continuing surveillance in states such as Texas, will provide information on the use of prostate cancer testing and facilitate a clearer delineation of the public health impact of this screening.

Although prostate cancer screening recommendations vary, one consistent element is that physicians should counsel patients about the risks for and potential benefits of treatment for early prostate cancer so that patients can participate in the decision making about whether to be screened. To counsel patients effectively about the risks for and benefits of treatment of early prostate cancer, physicians need access to current information and to incorporate it into their practices.

References

- 1. Bureau of Vital Statistics. Texas Cancer Mortality Statistics, 1990–1997. Austin, Texas: Texas Department of Health, 1998.
- American Cancer Society. Texas cancer facts & figures: a sourcebook for planning and implementing programs for cancer prevention and control, 2000. Austin, Texas: American Cancer Society, 2000.
- 3. Brawer MK. Prostate specific antigen: current status. Cancer Clinicians 1999;49:264-81.
- 4. American Cancer Society. Man to man newsletter: the PSA blood test & prostate cancer, 2000. Atlanta, Georgia: American Cancer Society, 2000.
- 5. American Foundation for Urologic Disease. Prostate cancer resource guide. 1999 ed. Baltimore, Maryland: American Foundation for Urologic Disease Inc., 1999.
- Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study. JAMA 2000;283:354–60.
- US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Washington, DC: US Department of Health and Human Services, Office of Public Health and Science, Office of Disease Prevention and Health Promotion, International Medical Publishing, Inc., 1996:119–34.
- 8. American Cancer Society. Prostate cancer and cancer detection guidelines, 1999. Atlanta, Georgia: American Cancer Society, 1999.
- 9. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548–52.

Update: West Nile Virus Activity — Northeastern United States, 2000

Surveillance data reported to CDC indicate intensified transmission and geographic expansion of the West Nile Virus (WNV) outbreak in the northeastern United States. Increasing reports of WNV infections in American crows, other avian species, and mosquitoes are being accompanied by reports of neurologic disease caused by WNV in humans, horses, and other mammals. This report updates human data through September 12 and animal data through September 8, 2000.

Since July 20, 12 persons have been hospitalized with serious central nervous system infections caused by WNV; eight had encephalitis, and four had meningitis. Patients ranged in age from 40 to 87 years; seven were men. Eight resided in Richmond County (Staten Island), New York, two in Kings County (Brooklyn), New York, and one in Hudson County, New Jersey. One person spent substantial time both in Brooklyn, New York, and Bergen County, New Jersey. Diagnoses were confirmed by ELISA for WNV-specific IgM

West Nile Virus — Continued

in cerebrospinal fluid. Subsequently, a four-fold rise in plaque-reduction neutralization antibody titer was demonstrated in four of these patients. Nine patients improved and were discharged from the hospital; three remain hospitalized.

Surveillance detected epizootic activity (15 WNV-infected dead birds and five infected mosquito pools in Staten Island; 10 infected dead birds in Hudson County; and two infected dead birds and one infected live hatch-year bird in Brooklyn) before onset of human illness on July 20 (first Staten Island case), August 6 (Hudson County), and August 15 (first Brooklyn case). The most recent onset of human illness was September 2.

Veterinary surveillance has detected WNV infection in five horses with severe neurologic disease (one horse each in Middlesex County, Massachusetts; Atlantic and Cape May counties, New Jersey; Staten Island, New York; and Washington County, Rhode Island). Onset of illness in these horses ranged from August 17 to 29. WNV infection has been confirmed in six bats (four live big brown bats [*Eptesicus fuscus*] from Albany County, New York, and two dead little brown bats [*Myotis lucifugus*] from Ontario County, New York) that originally were submitted for rabies testing. WNV infection was confirmed in a dead raccoon from New York County (Manhattan) that was found on August 19.

Mosquito surveillance has detected WNV in 237 mosquito pools in 15 counties in four states (223 pools in New York, eight in New Jersey, and three each in Connecticut and Massachusetts); 84 (36%) were from Staten Island. Of the 237 reported WNV-infected pools, 137 pools were *Culex pipiens/restuans*, 44 were *Culex pipiens*, 25 were *Culex salinarius* (23 from Staten Island, one from Bronx, and one from Queens, New York City), three were *Culex restuans*, three were *Aedes japonicus* (Orange, Rockland, and Westchester counties, New York), three were *Aedes vexans* (Brooklyn and Staten Island), two were *Aedes triseriatus* (Staten Island), and one was *Anopheles punctipennis* (Staten Island).

Avian surveillance has identified 1471 WNV-infected dead birds from 79 counties in six states (586 birds in New Jersey, 536 in New York, 241 in Connecticut, 103 in Massachusetts, four in Rhode Island, and one in New Hampshire). Since 1999, WNV has been identified in 56 avian species in the United States, 48 of which are native. In New York state, all types of submitted avian species are tested for WNV; of the 536 birds infected with WNV in 2000, 347 (65%) were American crows, 82 (15%) were blue jays, and 107 (20%) were other species. WNV antibody was documented in a serologic specimen collected August 4 from a previously seronegative sentinel chicken in Westchester County, New York.

Reported by: A Novello, MD, D White, PhD, L Kramer, PhD, C Trimarchi, MS, M Eidson, DVM, D Morse, MD, B Wallace, MD, P Smith, MD, State Epidemiologist, New York State Dept of Health; W Stone, MS, Dept of Environmental Conservation, Albany; B Cherry, VMD, PhD, B Edwin, J Kellachan, MPH, V Kulasekera, PhD, J Miller, MD, New York City Dept of Health. W Crans, PhD, Rutgers Univ, New Brunswick; F Sorhage, DVM, E Bresnitz, MD, State Epidemiologist, New Jersey Dept of Health and Senior Svcs. T Andreadis, PhD, Connecticut Agricultural Experiment Station, New Haven; M Cartter, MD, J Hadler, MD, State Epidemiologist, Connecticut Dept of Public Health. B Werner, PhD, A DeMaria, Jr, MD, State Epidemiologist, Massachusetts Dept of Public Health. U Bandy, MD, State Epidemiologist, Rhode Island Dept of Health. J Greenblatt, MD, State Epidemiologist, New Hampshire Dept of Health. National Wildlife Health Center, US Geologic Survey, Madison, Wisconsin. US Air Force. Arbovirus Diseases Br, Div of Vector Borne Infectious Diseases, National Center for Infectious Diseases; and EIS officers, CDC.

Editorial Note: WNV primarily circulates between birds and mosquitoes and probably only incidentally infects humans, horses, and other mammals. As a result, WNV activity in birds and mosquitoes in a specific area generally precedes WNV infection in humans

West Nile Virus — Continued

and horses (1). In 2000, the WNV surveillance system documented epizootic WNV infections in birds and mosquitoes as sentinel events before reports of severe neurologic WNV infection in humans and prompted immediate implementation of mosquito control. This confirms the pattern suspected in 1999 when an epizootic among American crows preceded the outbreak of 62 humans identified with WNV encephalitis and meningitis in the New York City metropolitan area (2).

Many counties with intense WNV activity in mosquito and avian populations during the summer of 2000 have not reported WNV infections in humans or other mammals. This is probably a result of a combination of intensive mosquito control activities and variable mosquito feeding behaviors, reservoir host behaviors, human outdoor activities, and use of protective measures. However, the 12 patients with severe central nervous system disease caused by WNV probably represent a small proportion of humans infected with WNV this season. Not all persons with neurologic WNV infection may have had the condition diagnosed or reported. Most persons with WNV infection are asymptomatic or have only nonspecific symptoms for which WNV testing is not performed routinely. A serosurvey in Queens, New York City, after the 1999 outbreak indicated that <1% of WNV-infected persons developed severe neurologic disease.

Health-care providers in areas with documented epizootic activity should consider WNV infection in persons with suspected viral meningitis (especially among adults) or encephalitis (regardless of age). Although severe WNV central nervous system disease may be more common in the elderly, eight of the 12 persons in this report were aged <65 years. In the 1999 WNV outbreak in the New York City area, the youngest patient was aged 5 years. WNV and other arboviruses (Eastern equine encephalitis, St. Louis encephalitis, and California serogroup viruses) can cause disease in the northeastern United States through the end of October and later in more southern locations.

The recent diagnosis of a WNV-infected horse in southern New Jersey (Cape May County), a major stopover for birds migrating south, underscores the need for enhanced avian morbidity and mortality surveillance in areas south of New York City and New Jersey. If ongoing local WNV epizootic activity is detected, public health measures should be enhanced to reduce the risk for human infection (*3*).

References

- 1. CDC. Guidelines for arbovirus surveillance in the United States. Washington, DC: US Department of Health and Human Services, April 1993.
- CDC. Guidelines for surveillance, prevention, and control of West Nile virus infection— United States. MMWR 2000;49:25–8.
- 3. CDC. Update: West Nile virus activity—Northeastern United States, January-August 7, 2000. MMWR 2000;49:714–7.




FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals ending September 9, 2000, with historical data

* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

		Cum. 2000		Cum. 2000
Anthrax		-	HIV infection, pediatric* [§]	149
Brucellosis*		45	Plague	5
Cholera		1	Poliomyelitis, paralytic	-
Congenital ru	bella syndrome	6	Psittacosis*	8
Cyclosporiasis	s* ,	32	Rabies, human	-
Diphtheria		-	Rocky Mountain spotted fever (RMSF)	298
	California serogroup viral*	42	Streptococcal disease, invasive, group A	2,040
	eastern equine*	-	Streptococcal toxic-shock syndrome*	62
	St. Louis*	1	Syphilis, congenital ¹	96
	western equine*	-	Tetanus	17
Ehrlichiosis	human granulocytic (HGE)*	104	Toxic-shock syndrome	109
	human monocytic (HME)*	73	Trichinosis	5
Hansen disea		42	Typhoid fever	227
	Ilmonary syndrome*t	22	Yellow fever	-
	emic syndrome, postdiarrheal*	108		

TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending September 9, 2000 (36th Week)

-: No reported cases.

*Not notifiable in all states. [†] Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases (NCID). [§] Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP). Last update August 27, 2000.

¹Updated from reports to the Division of STD Prevention, NCHSTP.

		DS	Chian	nydia⁺	Cruntos	poridiosis	NE		<i>coli</i> O157:H7	* LIS
Donouting Are-	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.
Reporting Area	2000⁵ 26,662	1999 30,098	2000 432,553	1999 451,458	2000 1,219	1999 1,634	2000 2,824	1999 2,293	2000 1,722	1999 1,830
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	1,428 25 26 20 895 63 399	1,515 52 38 11 987 74 353	14,504 982 682 366 6,353 1,681 4,440	14,592 753 663 334 6,225 1,599 5,018	58 13 13 19 11 2	116 19 10 25 50 1 11	250 18 27 27 102 11 65	289 24 24 24 24 126 22 69	255 22 24 28 111 12 58	275 U 25 14 135 23 78
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	5,921 637 3,150 1,202 932	7,764 890 4,062 1,461 1,351	38,241 N 16,184 5,555 16,502	46,230 N 19,292 8,478 18,460	98 65 8 5 20	290 91 160 20 19	285 191 10 84 N	152 98 15 39 N	108 38 9 31 30	82 - 14 49 19
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	2,480 400 254 1,368 331 127	1,975 296 244 930 401 104	69,767 18,318 8,788 17,001 17,564 8,096	75,359 20,719 8,172 22,704 14,240 9,524	286 75 32 7 58 114	435 33 27 66 34 275	571 166 97 129 88 91	708 136 55 438 79 N	217 44 62 - 63 48	345 127 40 81 59 38
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	615 116 65 287 2 6 43 96	674 114 63 341 4 13 43 96	24,681 4,797 3,332 8,523 352 1,238 2,323 4,116	25,544 5,176 3,017 9,030 626 1,090 2,385 4,220	154 21 51 21 9 12 34 6	147 55 41 16 14 6 13 2	459 100 149 104 14 35 39 18	377 128 78 31 10 37 72 21	360 111 76 77 15 38 32 11	425 141 62 47 16 53 99 7
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	7,336 131 845 500 483 43 454 553 873 3,454	8,244 112 889 318 501 46 554 758 1,230 3,836	87,907 1,875 9,004 2,199 10,792 1,177 15,431 7,850 17,502 22,077	96,629 1,866 9,031 N 10,165 1,239 15,779 12,780 23,825 21,944	263 5 10 9 12 3 19 - 100 105	234 - 11 7 17 2 6 - 97 94	247 - 21 - 49 11 53 16 38 59	206 6 12 - 51 9 48 16 21 43	151 - U 38 7 45 12 23 25	140 3 - 45 4 47 14 1 26
E.S. CENTRAL Ky. Tenn. Ala. Miss.	1,325 147 555 340 283	1,354 201 534 334 285	32,333 5,400 9,750 10,534 6,649	32,051 5,176 9,780 8,866 8,229	37 5 9 12 11	21 5 6 8 2	94 28 43 7 16	95 25 43 19 8	75 25 38 4 8	71 17 31 19 4
W.S. CENTRAL Ark. La. Okla. Tex.	2,716 127 461 219 1,909	3,181 122 597 94 2,368	66,989 3,580 12,810 5,554 45,045	62,786 3,929 11,420 5,494 41,943	58 8 9 33	59 1 22 5 31	140 50 5 13 72	73 9 10 17 37	177 30 38 9 100	93 7 11 15 60
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	1,034 11 16 7 238 107 339 101 215	1,167 7 15 7 207 67 603 102 159	25,854 960 1,255 540 7,688 3,213 8,048 1,558 2,592	23,713 1,099 1,200 528 5,035 3,567 8,663 1,441 2,180	88 8 6 5 38 9 9 10 3	73 10 7 10 29 10 N 6	301 26 45 12 115 17 36 40 10	183 11 21 11 70 8 23 26 13	153 - 2 61 14 27 49	144 U 16 13 47 4 15 36 13
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	3,807 347 112 3,247 15 86	4,224 245 136 3,770 13 60	72,277 8,595 3,456 56,765 1,633 1,828	74,554 8,034 4,290 58,729 1,287 2,214	177 N 14 163 -	259 N 80 179 -	477 138 115 190 23 11	210 73 46 81 - 10	226 97 63 56 1 9	255 119 55 71 1 9
Guam P.R. V.I. Amer. Samoa C.N.M.I.	14 762 25 -	11 937 25 - -	- 1,203 U U U U	355 U U U U U	- - U U U		N 5 U U U	N 5 U U U		U U U U U

 TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending September 9, 2000, and September 11, 1999 (36th Week)

N: Not notifiable. U: Unavailable. -: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands. * Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS). * Chlamydia refers to genital infections caused by *C. trachomatis.* Totals reported to the Division of STD Prevention, NCHSTP. * Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update August 27, 2000.

	Gonorrhea			atitis C; A, Non-B	Legio	nellosis		yme sease
Reporting Area	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999
UNITED STATES	226,154	245,105	2,183	1,867	602	632	7,460	9,884
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	4,070 59 71 44 1,733 418 1,745	4,493 45 81 36 1,726 404 2,201	13 2 3 3 5	13 2 5 3 3	25 2 3 9 3 6	47 3 4 11 15 5 9	1,719 40 13 584 215 867	2,890 22 4 11 632 281 1,940
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	23,197 4,685 6,643 4,180 7,689	27,342 4,421 8,895 5,302 8,724	429 50 - 354 25	87 42 - 45	126 48 - 9 69	142 35 21 12 74	4,423 2,293 10 1,151 969	5,171 2,694 119 1,329 1,029
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	42,131 11,168 4,124 11,071 12,413 3,355	47,151 12,437 4,358 15,923 10,247 4,186	166 8 1 10 147 -	679 1 40 621 16	157 72 32 8 32 13	189 55 26 27 46 35	258 69 26 11 152	518 33 15 17 11 442
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr.	10,996 1,912 740 5,400 15 200 882	11,103 1,948 748 5,340 61 124 1,060	456 5 1 438 - - 3	145 4 - 139 - - 2	49 3 12 26 - 2 2	36 5 11 14 - 2 4	175 100 20 38 1 - 1	202 107 20 53 1 -
Kans. S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	1,847 65,359 1,091 6,187 6,676 366 12,701 10,043 11,178 15,343	1,822 72,090 1,172 6,726 2,576 6,597 412 13,838 9,126 15,989 15,654	9 94 - 16 3 3 13 13 13 13 3 42	- 122 - 19 1 10 14 29 17 1 31	4 127 5 45 - 22 N 11 4 6 34	- 86 11 16 3 21 N 13 7 - 15	15 714 104 412 3 102 22 37 4 30	11 887 66 648 3 83 14 56 4 - 13
E.S. CENTRAL Ky. Tenn. Ala. Miss.	23,713 2,354 7,834 8,229 5,296	25,408 2,312 7,871 7,798 7,427	322 29 70 7 216	202 14 71 1 116	25 14 9 2	36 14 17 3 2	33 6 21 6	71 11 40 17 3
W.S. CENTRAL Ark. La. Okla. Tex.	35,048 1,994 9,360 2,415 21,279	35,902 2,012 9,003 2,721 22,166	296 9 183 6 98	339 20 232 15 72	18 - 9 2 7	8 1 4 3 -	14 4 2 - 8	39 4 7 7 21
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	6,752 28 60 38 2,086 705 2,691 165 979	6,614 33 59 20 1,693 700 3,086 137 886	271 4 3 207 20 12 13 1 1	132 4 37 25 24 22 6 8	27 1 4 20 10 1 5 4	34 - 9 1 5 12 6	23 9 8 - 1 3	11 - 3 2 1 - 2 2
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	14,888 1,514 463 12,438 220 253	15,002 1,375 620 12,486 210 311	136 22 24 88 - 2	148 13 12 123	48 15 N 33 -	54 10 N 43 1	101 6 7 86 2 N	95 4 10 81 N
Guam P.R. V.I. Amer. Samoa C.N.M.I.	- 423 U U U	41 231 U U U	- 1 U U U	1 - U U U	- 1 U U U	- U U U	N U U U	N U U U

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States,
weeks ending September 9, 2000, and September 11, 1999 (36th Week)

N: Not notifiable. U: Unavailable.

- : No reported cases.

weer	s enung	Coptonin				Salmon		
	Ma	laria	Rabie	s, Animal	NE	TSS		HLIS
Reporting Area	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999
UNITED STATES	763	973	4,049	4,584	22,889	25,048	18,772	23,038
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	36 5 1 2 10 5 13	34 3 2 4 13 4 8	530 95 9 44 194 45 143	600 110 35 73 136 72 174	1,385 93 98 88 751 83 272	1,518 96 95 65 853 70 339	1,440 70 87 89 775 114 305	1,591 83 100 58 865 121 364
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	138 50 50 19 19	276 49 156 41 30	760 532 U 120 108	867 620 U 133 114	2,690 809 665 571 645	3,326 852 1,004 687 783	2,735 881 661 393 800	3,569 925 1,013 804 827
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	76 16 4 27 22 7	118 18 13 50 30 7	117 40 - 19 53 5	130 29 10 7 66 18	3,307 909 439 911 621 427	3,668 832 352 1,163 694 627	1,721 453 377 1 626 264	3,245 733 338 1,133 677 364
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	34 13 2 6 2 - 5 6	48 21 12 11 - - 4	400 66 60 33 98 65 1 77	556 79 110 20 117 143 3 84	1,590 313 281 517 47 69 120 243	1,585 424 176 502 38 73 141 231	1,622 443 185 613 56 76 44 205	1,773 545 158 634 48 91 122 175
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	222 3 73 13 41 2 21 21 15 52	243 1 70 13 51 1 21 10 21 55	1,647 31 290 - 382 89 403 113 222 117	1,471 34 282 375 86 311 107 145 131	5,149 74 585 39 692 113 689 510 878 1,569	5,319 104 575 59 929 119 813 359 784 1,577	3,093 84 495 517 93 606 381 821 96	4,410 117 608 U 798 109 934 313 1,112 419
E.S. CENTRAL Ky. Tenn. Ala. Miss.	33 11 8 13 1	19 6 7 5 1	131 17 68 46	201 31 72 98	1,483 258 398 443 384	1,345 284 363 382 316	1,102 184 482 366 70	1,001 196 415 323 67
W.S. CENTRAL Ark. La. Okla. Tex.	10 3 2 5	14 2 10 2	65 20 - 45 -	341 14 - 76 251	1,795 453 118 278 946	2,362 385 503 291 1,183	2,619 329 407 175 1,708	1,865 120 430 237 1,078
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	36 1 2 - 19 - 6 4 4	33 4 3 1 15 2 2 4 2	187 52 9 43 - 17 55 9 2	149 47 32 1 8 54 4 3	1,949 69 91 48 533 166 505 349 188	2,125 45 68 41 561 295 616 362 137	1,398 - 14 451 149 451 333	1,882 1 68 41 541 232 564 386 49
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	178 22 31 122 3	188 18 15 143 1 11	212 - 7 184 21 -	269 2 260 7	3,541 359 225 2,758 42 157	3,800 449 332 2,720 35 264	3,042 376 253 2,238 23 152	3,702 623 364 2,484 18 213
Guam P.R. V.I. Amer. Samoa C.N.M.I. N: Not notifiable.	- U U U	- U U U Vailable.	- 53 U U U -: No repo	54 U U U	260 U U U	31 383 U U U		U U U U U

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States,weeks ending September 9, 2000, and September 11, 1999 (36th Week)

N: Not notifiable. U: Unavailable. -: No reported cases. * Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

		Shige		•		philis		
	NET		PHLIS		,	Secondary)		rculosis
Reporting Area	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999
UNITED STATES	12,751	10,618	6,604	6,414	4,027	4,645	8,053	10,814
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	243 10 4 3 165 19 42	527 4 13 5 440 17 48	239 12 7 150 28 42	497 - 11 3 416 16 51	54 1 36 4 12	41 - 3 22 1 14	277 9 14 4 168 25 57	285 13 10 1 157 29 75
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	1,476 559 583 210 124	711 202 242 164 103	856 177 402 135 142	519 48 172 163 136	192 8 89 35 60	206 16 87 48 55	1,559 181 856 369 153	1,814 222 928 378 286
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	2,735 240 1,167 639 518 171	1,978 322 183 787 292 394	737 96 124 2 472 43	1,065 97 56 621 232 59	783 55 279 195 218 36	824 65 280 298 152 29	858 200 60 421 119 58	1,081 175 94 523 220 69
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	1,481 359 398 497 12 5 71 139	857 164 23 560 2 11 57 40	1,182 499 217 361 14 3 9 79	580 191 22 283 2 6 43 33	41 4 10 22 - - 2 3	103 9 69 - 6 10	315 105 25 129 2 13 13 28	336 133 33 118 2 12 12 12 26
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	1,983 11 146 49 322 4 134 96 177 1,044	1,643 12 106 42 88 7 152 90 146 1,000	560 10 69 U 221 3 73 68 54 62	392 7 37 44 3 67 48 61 125	1,348 7 198 39 95 2 361 134 251 251 261	1,525 6 278 35 116 3 356 192 300 239	1,762 175 19 185 21 220 87 388 667	2,217 21 183 37 186 32 317 201 421 819
E.S. CENTRAL Ky. Tenn. Ala. Miss.	656 236 255 38 127	906 185 554 86 81	352 53 269 27 3	561 128 375 50 8	601 59 365 83 94	812 74 459 156 123	518 68 245 205	704 110 246 215 133
W.S. CENTRAL Ark. La. Okla. Tex.	1,317 154 80 79 1,004	1,745 61 142 409 1,133	1,899 44 124 29 1,702	754 20 77 132 525	575 70 156 91 258	728 44 208 142 334	833 134 73 92 534	1,499 119 115 119 1,146
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	764 6 41 5 141 97 317 58 99	644 7 16 3 114 84 321 44 55	386 U - 2 66 58 197 63	444 U 9 1 88 62 231 47 6	158 1 7 19 124 5	161 1 - 1 8 144 2 4	347 10 9 49 29 145 32 71	368 10 12 3 48 41 157 29 68
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	2,096 344 122 1,594 8 28	1,607 72 61 1,449 - 25	393 300 68 3 22	1,602 75 60 1,443 - 24	275 48 5 221 - 1	245 48 4 190 1 2	1,584 185 24 1,222 63 90	2,510 165 73 2,115 39 118
Guam P.R. V.I. Amer. Samoa C.N.M.I. N: Not potifiable	9 U U U	11 111 U U U		U U U U U	- 95 U U U	119 U U U	U U U U	52 151 U U U

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending September 9, 2000, and September 11, 1999 (36th Week)

N: Not notifiable. U: Unavailable. -: No reported cases. *Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

			1	ptemb	-	-		vеек)				
		<i>ienzae,</i> isive	H A	epatitis (Vi	ral), By Ty B	be	Indiger	20115	Meas Impo	les (Rubeo	la) Total	
	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.		Cum.		Cum.	Cum.	Cum.
Reporting Area	2000 [†] 805	1999 840	2000 7,773	1999 11,231	2000 4,560	1999 4,842	2000 1	2000 49	2000	2000 17	2000 66	1999 67
NEW ENGLAND	55	60	216	204	44	106		2	-	4	6	11
Maine N.H.	1 12	5 11	14 18	5 11	5 12	1 10	-	- 2	-	- 1	3	- 1
Vt.	4	5	9	6	6	2	-	-	-	3	3	-
Mass. R.I.	24 2	24 1	81 16	77 13	7 14	37 24	-	-	-	-	-	8
Conn.	12	14	78	92	-	32	-	-	-	-	-	2
MID. ATLANTIC Upstate N.Y.	134 70	146 59	769 147	801 177	660 94	611 136	-	14 9	-	5 -	19 9	5 2
N.Y. City N.J.	28 27	44 38	238 118	248 96	314 83	183 93	-	5	-	4	9	3
Pa.	9	5	266	280	169	199	-	-	-	1	1	-
E.N. CENTRAL Ohio	114 42	142 48	944 200	2,124 468	494 78	509 70	-	8 2	-	-	8 2	2
Ind. III.	25 40	20 59	60 341	77 518	36 85	32 44	-	-4	-	-	- 4	1
Mich. Wis.	7	11 4	330 13	1,007 54	294 1	336 27	-	2	-	-	2	1
W.N. CENTRAL	- 46	53	653	533	542	192	-	- 2	-	- 1	3	-
Minn. Iowa	24	33 2	164 62	54 101	27 34	37 28	-	2	-	1	1 2	-
Mo.	13	5	321	316	435	106	-	-	-	-	-	-
N. Dak. S. Dak.	1 -	1 2	2 1	2 8	2 1	- 1	-	-	-	-	-	-
Nebr. Kans.	4 4	4 6	21 82	39 13	24 19	15 5	-	-	-	-	-	-
S. ATLANTIC	213	187	994	1,275	851	780		3	-	-	3	5
Del. Md.	- 56	- 49	- 146	2 221	- 86	1 110	U -	-	U	-	-	-
D.C. Va.	- 31	4 14	20 106	53 110	27 104	19 66	-	2	-	-	- 2	- 3
W. Va. N.C.	6 19	6 28	49 111	29 110	9 165	20 182	-	-	-	-		-
S.C. Ga.	11 54	5 51	44 181	29 346	11 142	57 99	-	-	-	-	-	-
Fla.	36	30	337	375	307	226	-	1	-	-	1	2
E.S. CENTRAL Ky.	37 12	51 6	302 35	292 54	327 57	343 33	-	-	-	-	-	2 2
Tenn.	17	27	110	116	160	171	-	-	-	-	-	-
Ala. Miss.	7 1	15 3	46 111	43 79	36 74	68 71	-	-	-	-	-	-
W.S. CENTRAL	46 2	51 2	1,211	2,222 32	454	855 54	-	-	-	-	-	7
Ark. La.	7	11	103 30	170	69 52	139	-	-	-	-	-	-
Okla. Tex.	35 2	34 4	199 879	390 1,630	113 220	112 550	-	-	-	-	-	- 7
MOUNTAIN	77	68	698	909	359	422	-	11		1	12	1
Mont. Idaho	1 3	1 1	4 19	16 31	5 6	16 22	U -	-	U -	-	-	-
Wyo. Colo.	1 11	1 11	39 141	6 168	23 60	10 72	-	- 1	-	- 1	2	-
N. Mex. Ariz.	17 36	18 30	58 350	38 515	74 142	136 103	-	-	-	-	-	- 1
Utah Nev.	7 1	4	40 47	36 99	17 32	24 39	U	3 7	U	-	3 7	-
PACIFIC	83	82	4, 1,986	2,871	829	1,024	1	9	_	6	, 15	34
Wash. Oreg.	5 21	3 29	198 139	222 187	70 70	46 78	-	2	-	1	3	5 12
Caliť.	28 6	39	1,627	2,438	671	877	-	5	-	3	8	16
Alaska Hawaii	23	5 6	9 13	7 17	8 10	13 10	- 1	1 1	-	2	1 3	- 1
Guam	- 1	2	- 87	1 218	- 96	2 160	U	-	U	-	-	1
P.R. V.I.	U	U	U	U	U	U	U	Ŭ	Ü	U	U	Ŭ
Amer. Samoa <u>C.N.M.I.</u>	U U	U U	U U	U U	U U	U U	U U	U U	U U	U U	U U	U U

TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending September 9, 2000, and September 11, 1999 (36th Week)

N: Not notifiable. U: Unavailable. - : No reported cases. *For imported measles, cases include only those resulting from importation from other countries. *Of 160 cases among children aged <5 years, serotype was reported for 68 and of those, 18 were type b.

		jococcal ease	Mumps				Pertussis	-		Rubella	
Reporting Area	Cum. 2000	Cum. 1999	2000	Cum. 2000	Cum. 1999	2000	Cum. 2000	Cum. 1999	2000	Cum. 2000	Cum. 1999
UNITED STATES	1,488	1,752	2000	256	259	102	3,968	4,209	1	110	225
NEW ENGLAND	90	81	-	4	6	4	914	496	1	12	7
Maine N.H.	9 9	5 11	-	-	- 1	- 3	31 82	- 77	-	- 2	-
Vt. Mass.	2 53	4 45	-	- 1	1	1	173 577	41 346	-	- 8	- 7
R.I.	8	4	-	1	-	-	14	20	1	1	-
Conn. MID. ATLANTIC	9 143	12 168	- 1	2 19	- 34	- 5	37 374	12 690	-	1 9	- 30
Upstate N.Y.	46	46	1	8	7	5	170	537	-	2	18
N.Y. City N.J.	30 31	49 39	-	4 3	9 1	-	44 34	37 19	-	7	5 4
Pa.	36	34	-	4	17	-	126	97	-	-	3
E.N. CENTRAL Ohio	252 63	315 111	1	27 7	34 11	16 9	459 238	383 156	-	1	2
Ind. III.	37 64	45 82	1	1 6	4	6	68 45	52 67	-	- 1	1 1
Mich.	68	46	-	13	8	1	53	39	-	-	-
Wis.	20	31	-	-	2	-	55	69 204	-	-	-
W.N. CENTRAL Minn.	128 17	171 38	-	17	9 1	12 9	325 191	284 127	-	-	124 5
lowa Mo.	22 72	31 62	-	6 5	4 1	1 1	40 49	43 52	-	-	30 2
N. Dak. S. Dak.	2 5	3 11	-	-	-	1	3	4 5	-	-	-
Nebr.	3 4 6	9 17	-	3	- 3	-	9 30	4 49	-	-	87
Kans. S. ATLANTIC	6 243	287	-	3 40	3 39	- 18	30 329	49 294	-	- 61	- 34
Del.	240	8	U	- - 9	- 3	U	8	4	U	-	-
Md. D.C.	-	44 3	-	-	2	1	77 3	93	-	-	1 -
Va. W. Va.	35 10	36 5	-	8	8	14 -	58 1	17 2	-	-	-
N.C. S.C.	32 18	34 35	-	5 11	8 3	2	76 23	76 14	-	52 7	33
Ga. Fla.	38 88	49 73	-	2	4 11	- 1	27 56	26 62	-	2	-
E.S. CENTRAL	107	122	-	6	11	1	84	73	-	5	2
Ky. Tenn.	24 44	24 49	-	2	-	-	40 25	22 30	-	1	
Ala.	29	30	-	2	8	1	18	18	-	3	2
Miss. W.S. CENTRAL	10 103	19 182	-	2 23	3 36	- 6	1 207	3 157	-	- 4	- 6
Ark.	12	31	-	2	-	-	207 29 3	18	-	-	-
La. Okla.	28 22	54 27	-	3	10 1	3	13	9 30	-	-	-
Tex.	41	70	-	18	25	3	162	100	-	4	6
MOUNTAIN Mont.	105 4	106 2	Ū	18 1	10	15 U	528 24	501 2	Ū	2	16 -
ldaho Wyo.	6	8 4	-	2	1	2	48 5	117 2	-	-	-
Cólo. N. Mex.	28 7	27 13	-	1 1	3 N	13	296 74	188 71	-	1	1
Ariz.	50	32	-	4	-	-	57	66	-	1	13
Utah Nev.	7 3	13 7	U -	4 5	3 3	U -	15 9	51 4	U -	-	1 1
PACIFIC	317	320	-	102	80	25	748	1,331	-	16	4
Wash. Oreg.	38 50	51 55	Ν	6 N	2 N	20 4	248 96	544 31	-	7	-
Calif. Alaska	215 6	202 6	-	75 7	65 1	1	358 19	722 4	-	9	4
Hawaii	8	6	-	14	12	-	27	30	-	-	-
Guam P.R.	- 6	1 9	U	-	1	U	- 2	2 19	U	-	-
V.I. Amer. Samoa	Ŭ U	Ŭ	U U	U U	U U	U U	2 U U	19 U U	U U	U U	U U
C.N.M.I.	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ

TABLE III. (Cont'd) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending September 9, 2000, and September 11, 1999 (36th Week)

N: Not notifiable. U: Unavailable.

- : No reported cases.

		All Cau	ises, By	Age (Ye	ears)		P&I [†]			All Cau	ises, By	Age (Y	'ears)		P&I⁺
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total
NEW ENGLAND Boston, Mass. Bridgeport, Conn Cambridge, Mass Fall River, Mass. Hartford, Conn. Lowell, Mass. Lynn, Mass. New Bedford, Ma New Haven, Conn Providence, R.I. Somerville, Mass. Springfield, Mass Waterbury, Conn. Worcester, Mass. MID. ATLANTIC Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J.	20 28 27 9 55. 24 49 2 49 2 49 2 49 33 15 99 32 10	419 115 19 16 23 34 22 9 21 29 21 29 30 22 30 22 30 22 30 22 30 22 30 22 30 22 30 22 30 22 30 22 30 22 30 27 72 20 27 20 27 20 27 20 27 20 20 20 20 20 20 20 20 20 20 20 20 20	44 5 2 4 14 4 - 9 4 - 6 3 5 3 12 3 3 21 6 2	37 13 3 2 4 1 - 2 2 2 2 - 3 1 4 136 1 - 3 3 1	12 3 - 2 - 1 1 2 - 1 1 2 - 1 1 1 2 8 - - 2 2 - - - - - - - - - - - - - -	10 2 - - 1 1 - - - 3 2 2 8 1 - - 28 1 - - - - - - - - - - - - - - - - - -	57 12 32 7 1 4 57 4 66 9 3 1 7 1	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, F Tampa, Fla. Washington, D.U. Wilmington, De E.S. CENTRAL Birmingham, Al Chattanooga, Te Knoxville, Tenn. Lexington, Ky. Memphis, Tenn Mobile, Ala.	88 38 50 44 -1a. 41 136 C. 100 I. 23 rnn. 46 snn. 46 50 . 160 64 1a. 32	60 78 43 21 30 30 101 54 23 441 100 36 61 32 89 41 21	195 U 34 152 23 10 15 8 8 27 23 - 164 26 7 28 15 46 9 11	78 U 16 6 0 18 5 3 2 1 5 2 1 5 8 12 3 5 1 1 6 8 12 3 5 1 1 6 8 12 3 5 1 1 6 8 12 1 6 10 10 10 10 10 10 10 10 10 10 10 10 10	34 U 755 24 1 8 1 - 28 6 - 2 1 22	22 U 1 2 3 - 1 2 3 2 1 7 - 20 5 - 1 1 7 - 20 5 - 1 1 7 2 	54 U 14 4 13 5 1 3 5 3 5 1 - 50 11 2 3 6 9 2 2
Erie, Pa.§ Jersey City, N.J. New York City, N.Y. Newark, N.J. Paterson, N.J. Philadelphia, Pa. Pittsburgh, Pa.§ Reading, Pa. Rochester, N.Y. Schenectady, N.Y. Scranton, Pa.§ Syracuse, N.Y. Trenton, N.J. Utica, N.Y. Yonkers, N.Y.	62 24 U 42 22 110 28 39 56 13 18 U	27 26 698 30 16 U 328 83 23 34 48 7 14 U	194 17 6 U 7 1 18 5 3 3 3 4 U	4 89 14 2 2 7 - 2 3 3 - U	1 1 21 - - 1 - - - - - - - -	- 19 - U 1 - - 2 - U	3 48 1 4 U 6 2 6 4 2 4 - 2 U	Nashville, Tenn. W.S. CENTRAL Austin, Tex. Baton Rouge, La Corpus Christi, Dallas, Tex. El Paso, Tex. El Paso, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La San Antonio, Te Shreveport, La. Tulsa, Okla.	Tex. 46 164 56 273 54 . 84 x. 173 70 108	779 32 30 32 94 46 58 170 36 36 127 45 73	22 242 11 7 7 36 6 19 66 3 21 33 21 33 21	13 108 4 6 5 21 3 6 29 1 9 10 4 10	13 41 - 1 7 - 2 6 1 15 2 4 3	4 22 1 1 6 1 1 2 1 1 1 5 1	15 72 3 1 8 3 3 13 2 7 13 6 13
E.N. CENTRAL Akron, Ohio Canton, Ohio Chicago, III. Cincinnati, Ohio Cleveland, Ohio Dayton, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind. Gary, Ind. Grand Rapids, Mii Indianapolis, Ind. Lansing, Mich. Milwaukee, Wis. Peoria, III. South Bend, Ind. Toledo, Ohio Youngstown, Ohi W.N. CENTRAL Des Moines, Iowa Duluth, Minn. Kansas City, Kans Kansas City, Kans Kansas City, Kans St. Louis, Mo. St. Louis, Mo.	156 29 75 38 40 26 91 694 51 31 51 315 113 25	$\begin{array}{c} 1,175\\ 31\\ 31\\ 266\\ 64\\ 100\\ 65\\ 104\\ 27\\ 40\\ 10\\ 39\\ 916\\ 43\\ 28\\ 17\\ 855\\ 494\\ 24\\ 10\\ 75\\ 19\\ 103\\ 52\\ 87\\ 19\\ 103\\ 52\\ 87\\ 51\\ 103\\ 52\\ 87\\ 51\\ 103\\ 52\\ 87\\ 51\\ 103\\ 52\\ 87\\ 51\\ 103\\ 52\\ 87\\ 51\\ 103\\ 52\\ 87\\ 51\\ 103\\ 52\\ 87\\ 51\\ 103\\ 52\\ 87\\ 51\\ 103\\ 52\\ 87\\ 51\\ 103\\ 52\\ 87\\ 51\\ 103\\ 52\\ 87\\ 51\\ 103\\ 52\\ 87\\ 51\\ 103\\ 52\\ 87\\ 51\\ 103\\ 52\\ 87\\ 51\\ 103\\ 52\\ 87\\ 51\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103\\ 10$	8 9 126 265 3 6 4 9 310 23 9 8 7 11 4 119 9 3 2 15 4 25 13 6 18 119 119 119 119 119 119 119 119 119	147 3 2 4 8 9 13 4 16 2 1 4 12 3 7 1 4 1 8 1 3 6 4 3 2 10 5 2 6 1 3	57 123 2 2 2 2 7 - 1 2 6 6 6 - 2 1 - 2 - 2 8 2 1 1 9 - 4 3 4 2 2	46 - 22 - 4 - 4 - 2 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 2 - 2 - 4 - 4 - 2 	1763&23;365·2·1;31542152 &&2351;37;07;0	MOUNTAIN Albuquerque, N Boise, Idaho Colo. Springs, C Denver, Colo. Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, U Tucson, Ariz. PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif. Glendale, Calif. Honolulu, Hawa Long Beach, Cal Los Angeles, Ca Pasadena, Calif. Portland, Oreg. Sacramento, Ca San Jose, Calif. Sant Francisco, C San Jose, Calif. Santa Cruz, Cali Seattle, Wash. Tocma.	35 colo. 54 74 187 29 163 28 tah 90 126 1,185 13 76 25 ii 51 if. 78 lif. 364 34 iif. 43 lif. U . 141 . 30 f. 24 43 25 ii 51 ii 78 ii 51 ii 78 ii 78 i 78 i	$\begin{array}{c} 119 \\ 17 \\ 104 \\ 20 \\ 63 \\ 77 \\ 822 \\ 9 \\ 52 \\ 222 \\ 339 \\ 59 \\ 236 \\ 20 \\ 29 \\ 0 \\ 95 \\ 90 \\ 95 \\ 90 \\ 27 \end{array}$	169 14 9 11 19 3 5 31 5 2 18 4 19 2 9 9 73 5 8 U 2 U 2 3 17 8 10 1,9 19 1,9 19 1,9 19 19 19 19 19 19 19 19 10 19 10 19 19 10 19 10 19 10 19 10 19 10 19 10 19 10 19 10 19 10 19 10 19 10 10 10 10 10 10 10 10 10 10 10 10 10	78 7 1 2 7 20 5 15 2 10 9 86 4 1 1 6 37 4 2 U11 U 7 1 6 4 2 7 64 2 764	33 - - 3 1 1 1 6 1 3 7 36 - 1 - 1 4 12 2 2 U 3 - 3 1 4 297	21 - - - - - - - - - - - - -	49 4 2 2 4 1 1 0 2 7 6 8 8 1 4 4 5 9 23 1 3 U 8 U 2 3 7 3 5 6 47 6 47

TABLE IV. Deaths in 122 U.S. cities,* week endingSeptember 9, 2000 (36th Week)

U: Unavailable. -:No reported cases. *Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. *Pneumonia and influenza. *Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. *Total includes unknown ages.

Notice to Readers

Satellite Broadcast on HIV Prevention

"HIV Prevention Update: Men Who Have Sex With Men," a satellite broadcast, is scheduled for Thursday, November 30, 2000, at 1–3 p.m. eastern standard time. CDC and the Public Health Training Network are sponsoring this forum, which will focus on activities and resources to prevent human immunodeficiency virus (HIV) infection among men who have sex with men (MSM). Viewers will hear about CDC activities and programs occurring throughout the country.

This broadcast is designed for organizations and persons who provide HIV prevention and other health and social services for MSM. This audience includes public health programs, community-based organizations, and policymakers. Speakers will discuss the HIV epidemic among MSM, factors contributing to increases in risk behaviors, effective HIV prevention programs for MSM, and resources and technical assistance for conducting HIV prevention programs for this population. Viewers can fax questions and comments before and during the broadcast.

Additional information for organizations and potential viewers is available through the World-Wide Web site for the broadcast, http://www.cdcnpin.org/broadcast, and CDC's Fax Information System, telephone (888) 232-3299, by entering document number 130030 and a return fax number. Organizations setting up viewing sites are encouraged to register online or by fax as early as possible so that viewers may access information about viewing locations when visiting the web site or calling the information line.

Contributors to the Produ	ction of the <i>MMWR</i> (Weekly)
Weekly Notifiable Disease Morbi	dity Data and 122 Cities Mortality Data
Samuel L. Gros	eclose, D.V.M., M.P.H.
State Support Team Robert Fagan Jose Aponte Gerald Jones David Nitschke Scott Noldy Carol A. Worsham	<i>CDC Operations Team</i> Carol M. Knowles Deborah A. Adams Willie J. Anderson Patsy A. Hall Suzette A. Park Felicia J. Perry Pearl Sharp
Inf	ormatics
T. Deme	etri Vacalis, Ph.D.
Michele D. Renshaw	Erica R. Shaver

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/Publications/mmwr. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Con	ector, Centers for Disease trol and Prevention affrey P. Koplan, M.D., M.P.H.	Acting Director, Epidemiology Program Office Barbara R. Holloway, M.P.H.	Writers-Editors, <i>MMWR</i> (Weekly) Jill Crane David C. Johnson						
Pub Con	uty Director for Science and lic Health, Centers for Disease trol and Prevention avid W. Fleming, M.D.	Editor, <i>MMWR</i> Series John W. Ward, M.D. Acting Managing Editor, <i>MMWR</i> (Weekly) Teresa F. Rutledge	Desktop Publishing Michael T. Brown Lynda G. Cupell Morie M. Higgins						
	☆U.S. Government Printing Office: 2000-533-206/28038 Region IV								